In other autoimmune diseases, such as spondyloarthropathy and Behcet’s disease, TLR2 expression is downregulated after infliximab therapy, supporting the role of TLR2 in the response to the anti-TNFα therapy (De Rycke et al., 2005; Keino et al., 2011). The gene discussed is TLR2; the disease is spondyloarthropathy.